Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pyruvic Acid | 23 | 2022 | 200 | 2.540 |
Why?
|
| Magnetic Resonance Spectroscopy | 27 | 2023 | 3760 | 1.780 |
Why?
|
| Carbon Isotopes | 29 | 2013 | 469 | 1.560 |
Why?
|
| Magnetic Resonance Imaging | 43 | 2023 | 35423 | 0.840 |
Why?
|
| Metronidazole | 1 | 2023 | 217 | 0.830 |
Why?
|
| Pyruvates | 7 | 2013 | 87 | 0.630 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2022 | 2017 | 0.450 |
Why?
|
| Stomach Neoplasms | 1 | 2022 | 1333 | 0.430 |
Why?
|
| Alanine | 9 | 2012 | 572 | 0.380 |
Why?
|
| Phantoms, Imaging | 11 | 2022 | 2480 | 0.340 |
Why?
|
| Rats, Wistar | 15 | 2013 | 1903 | 0.340 |
Why?
|
| Lactic Acid | 10 | 2012 | 1132 | 0.340 |
Why?
|
| Rats | 27 | 2023 | 24273 | 0.310 |
Why?
|
| Image Enhancement | 7 | 2013 | 2921 | 0.300 |
Why?
|
| Gyrus Cinguli | 3 | 2022 | 1091 | 0.300 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 7179 | 0.250 |
Why?
|
| Brain Neoplasms | 7 | 2021 | 8860 | 0.250 |
Why?
|
| Kidney | 7 | 2017 | 7183 | 0.240 |
Why?
|
| Lactates | 3 | 2022 | 432 | 0.240 |
Why?
|
| Radiopharmaceuticals | 5 | 2012 | 2662 | 0.240 |
Why?
|
| Somatosensory Cortex | 2 | 2009 | 528 | 0.230 |
Why?
|
| Algorithms | 11 | 2018 | 13885 | 0.230 |
Why?
|
| Lactate Dehydrogenases | 1 | 2022 | 26 | 0.210 |
Why?
|
| Pain Threshold | 2 | 2003 | 585 | 0.210 |
Why?
|
| Brain | 14 | 2022 | 26413 | 0.210 |
Why?
|
| Hexokinase | 1 | 2022 | 125 | 0.200 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2022 | 192 | 0.200 |
Why?
|
| Reference Values | 5 | 2022 | 4982 | 0.200 |
Why?
|
| Solubility | 1 | 2023 | 1083 | 0.200 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2019 | 3328 | 0.200 |
Why?
|
| Imaging, Three-Dimensional | 6 | 2013 | 4044 | 0.200 |
Why?
|
| Self-Assessment | 1 | 2003 | 390 | 0.190 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2010 | 2214 | 0.190 |
Why?
|
| Inositol | 1 | 2021 | 218 | 0.190 |
Why?
|
| Glioma | 4 | 2019 | 3401 | 0.190 |
Why?
|
| Cerebrovascular Circulation | 5 | 2022 | 2732 | 0.190 |
Why?
|
| Alzheimer Disease | 1 | 2021 | 8037 | 0.180 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2020 | 186 | 0.180 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2020 | 223 | 0.170 |
Why?
|
| Liver | 5 | 2012 | 7472 | 0.160 |
Why?
|
| Gadolinium DTPA | 3 | 2017 | 836 | 0.160 |
Why?
|
| Glutamic Acid | 2 | 2022 | 1169 | 0.160 |
Why?
|
| Organometallic Compounds | 3 | 2017 | 665 | 0.160 |
Why?
|
| Image Processing, Computer-Assisted | 10 | 2019 | 8950 | 0.150 |
Why?
|
| Myocardium | 4 | 2022 | 4776 | 0.150 |
Why?
|
| Reproducibility of Results | 9 | 2022 | 19907 | 0.150 |
Why?
|
| Signal Processing, Computer-Assisted | 3 | 2017 | 1537 | 0.150 |
Why?
|
| Contrast Media | 8 | 2020 | 5300 | 0.150 |
Why?
|
| Perfusion Imaging | 1 | 2019 | 195 | 0.150 |
Why?
|
| Animals | 33 | 2023 | 168788 | 0.150 |
Why?
|
| Liver Neoplasms | 2 | 2010 | 4252 | 0.150 |
Why?
|
| Tissue Distribution | 6 | 2012 | 2335 | 0.150 |
Why?
|
| Carbon Radioisotopes | 3 | 2013 | 592 | 0.140 |
Why?
|
| Capillary Permeability | 1 | 2019 | 798 | 0.130 |
Why?
|
| Mice, Nude | 1 | 2022 | 3689 | 0.130 |
Why?
|
| Glioblastoma | 2 | 2021 | 3481 | 0.130 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2017 | 1442 | 0.130 |
Why?
|
| Manganese | 1 | 2017 | 408 | 0.130 |
Why?
|
| Breast | 3 | 2017 | 1969 | 0.120 |
Why?
|
| Caffeine | 3 | 2003 | 699 | 0.120 |
Why?
|
| Ethanol | 2 | 2012 | 1342 | 0.120 |
Why?
|
| Spin Labels | 3 | 2022 | 332 | 0.120 |
Why?
|
| Sodium Lactate | 1 | 2012 | 3 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 2503 | 0.110 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2000 | 1101 | 0.110 |
Why?
|
| Caproates | 1 | 2012 | 18 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2022 | 2455 | 0.110 |
Why?
|
| Prefrontal Cortex | 1 | 2003 | 2148 | 0.110 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2012 | 142 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2021 | 2038 | 0.100 |
Why?
|
| tau Proteins | 1 | 2021 | 1868 | 0.100 |
Why?
|
| Brain Mapping | 4 | 2009 | 6671 | 0.090 |
Why?
|
| Physics | 1 | 2011 | 87 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2012 | 8302 | 0.090 |
Why?
|
| Least-Squares Analysis | 2 | 2007 | 379 | 0.090 |
Why?
|
| Sensitivity and Specificity | 7 | 2012 | 14726 | 0.090 |
Why?
|
| Isoflurane | 1 | 2012 | 380 | 0.090 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2012 | 507 | 0.080 |
Why?
|
| Pain | 2 | 2003 | 4987 | 0.080 |
Why?
|
| Arthritis, Experimental | 1 | 2011 | 291 | 0.080 |
Why?
|
| Language Disorders | 1 | 2009 | 140 | 0.080 |
Why?
|
| Anesthetics, General | 1 | 2010 | 152 | 0.080 |
Why?
|
| Echo-Planar Imaging | 1 | 2012 | 659 | 0.080 |
Why?
|
| Amyloid beta-Peptides | 1 | 2021 | 3585 | 0.080 |
Why?
|
| Positron-Emission Tomography | 2 | 2021 | 6274 | 0.080 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2009 | 247 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 3703 | 0.080 |
Why?
|
| Magnetics | 1 | 2010 | 607 | 0.070 |
Why?
|
| Male | 34 | 2021 | 350027 | 0.070 |
Why?
|
| Models, Biological | 5 | 2011 | 9582 | 0.070 |
Why?
|
| Metabolic Clearance Rate | 3 | 2012 | 379 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2012 | 1126 | 0.070 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 996 | 0.070 |
Why?
|
| Motion | 3 | 2005 | 798 | 0.070 |
Why?
|
| Humans | 32 | 2022 | 744220 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 5529 | 0.070 |
Why?
|
| Equipment Failure Analysis | 2 | 2010 | 868 | 0.070 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2009 | 403 | 0.070 |
Why?
|
| Molecular Imaging | 1 | 2012 | 831 | 0.070 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2009 | 333 | 0.070 |
Why?
|
| Models, Chemical | 1 | 2007 | 626 | 0.060 |
Why?
|
| Coma | 1 | 2009 | 475 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 9230 | 0.060 |
Why?
|
| Adenocarcinoma | 3 | 2020 | 6352 | 0.060 |
Why?
|
| Kinetics | 4 | 2012 | 6474 | 0.060 |
Why?
|
| Mitochondria | 2 | 2013 | 3520 | 0.060 |
Why?
|
| Artifacts | 4 | 2012 | 1903 | 0.060 |
Why?
|
| Human Experimentation | 1 | 2003 | 127 | 0.050 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2022 | 87 | 0.050 |
Why?
|
| Acetazolamide | 1 | 2002 | 100 | 0.050 |
Why?
|
| Coffee | 2 | 2003 | 578 | 0.050 |
Why?
|
| Auditory Cortex | 2 | 2003 | 346 | 0.050 |
Why?
|
| Temporal Lobe | 1 | 2009 | 1670 | 0.050 |
Why?
|
| Prostatic Neoplasms | 3 | 2009 | 11074 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 5221 | 0.050 |
Why?
|
| Oxygen | 3 | 2022 | 4187 | 0.050 |
Why?
|
| Electromagnetic Fields | 1 | 2003 | 298 | 0.050 |
Why?
|
| Ketones | 1 | 2022 | 188 | 0.050 |
Why?
|
| Mice | 5 | 2022 | 81178 | 0.050 |
Why?
|
| Neuronal Plasticity | 1 | 2009 | 1422 | 0.050 |
Why?
|
| Rotation | 3 | 2009 | 523 | 0.050 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2009 | 1541 | 0.050 |
Why?
|
| Visual Cortex | 3 | 2003 | 1149 | 0.040 |
Why?
|
| Peripheral Nerves | 1 | 2003 | 477 | 0.040 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2019 | 85 | 0.040 |
Why?
|
| Adult | 14 | 2022 | 214035 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 2020 | 534 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11493 | 0.040 |
Why?
|
| Disease Models, Animal | 4 | 2011 | 18027 | 0.040 |
Why?
|
| Heart Failure | 1 | 2022 | 10905 | 0.040 |
Why?
|
| Electric Stimulation | 1 | 2003 | 1770 | 0.040 |
Why?
|
| Leg | 1 | 2003 | 1117 | 0.040 |
Why?
|
| Arousal | 1 | 2003 | 1165 | 0.040 |
Why?
|
| Corpus Callosum | 1 | 2002 | 737 | 0.040 |
Why?
|
| Hot Temperature | 1 | 2003 | 1355 | 0.040 |
Why?
|
| Nerve Net | 1 | 2009 | 2175 | 0.040 |
Why?
|
| Tretinoin | 1 | 2020 | 517 | 0.040 |
Why?
|
| Female | 17 | 2021 | 380197 | 0.040 |
Why?
|
| Whole Body Imaging | 2 | 2010 | 280 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2018 | 288 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2003 | 1869 | 0.040 |
Why?
|
| Half-Life | 1 | 2017 | 659 | 0.040 |
Why?
|
| Pain Measurement | 2 | 2003 | 3419 | 0.040 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2022 | 1123 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 15070 | 0.030 |
Why?
|
| Papio | 1 | 2017 | 656 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2020 | 1547 | 0.030 |
Why?
|
| Middle Aged | 12 | 2021 | 213367 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2022 | 2025 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 13096 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2021 | 2619 | 0.030 |
Why?
|
| Renal Artery | 1 | 2017 | 398 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2000 | 20817 | 0.030 |
Why?
|
| Breast Diseases | 1 | 1998 | 443 | 0.030 |
Why?
|
| Reference Standards | 1 | 2019 | 1025 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 7908 | 0.030 |
Why?
|
| Aorta, Abdominal | 1 | 2017 | 645 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2022 | 1808 | 0.030 |
Why?
|
| Acoustic Stimulation | 3 | 2003 | 1217 | 0.030 |
Why?
|
| Time Factors | 5 | 2013 | 40063 | 0.030 |
Why?
|
| Acetoacetates | 1 | 2013 | 22 | 0.030 |
Why?
|
| Acetylcarnitine | 1 | 2013 | 9 | 0.030 |
Why?
|
| Central Nervous System Stimulants | 1 | 2002 | 1148 | 0.030 |
Why?
|
| Aged | 7 | 2022 | 163253 | 0.030 |
Why?
|
| Dobutamine | 1 | 2013 | 123 | 0.030 |
Why?
|
| Meglumine | 1 | 2013 | 149 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2019 | 1462 | 0.030 |
Why?
|
| Acetyl Coenzyme A | 1 | 2013 | 74 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2003 | 4199 | 0.030 |
Why?
|
| Disulfiram | 1 | 2012 | 57 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2007 | 5102 | 0.030 |
Why?
|
| Functional Laterality | 2 | 2009 | 2290 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 5755 | 0.030 |
Why?
|
| Photic Stimulation | 3 | 2003 | 2027 | 0.030 |
Why?
|
| RNA Interference | 1 | 2020 | 2890 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2022 | 2895 | 0.020 |
Why?
|
| Software | 2 | 2019 | 4442 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2020 | 4217 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 3505 | 0.020 |
Why?
|
| Monocytes | 1 | 2020 | 2594 | 0.020 |
Why?
|
| Tritium | 1 | 2011 | 746 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 6612 | 0.020 |
Why?
|
| Glucose | 1 | 2022 | 4396 | 0.020 |
Why?
|
| Heterocyclic Compounds | 1 | 2011 | 249 | 0.020 |
Why?
|
| Bicarbonates | 1 | 2011 | 313 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2012 | 1104 | 0.020 |
Why?
|
| Single-Blind Method | 2 | 2003 | 1590 | 0.020 |
Why?
|
| Language Tests | 1 | 2009 | 200 | 0.020 |
Why?
|
| Prostate | 1 | 2017 | 1773 | 0.020 |
Why?
|
| Glasgow Outcome Scale | 1 | 2009 | 109 | 0.020 |
Why?
|
| Median Nerve | 1 | 2009 | 132 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 5867 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2013 | 782 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 3584 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2003 | 6546 | 0.020 |
Why?
|
| Computer Systems | 1 | 2009 | 483 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2012 | 2007 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 21824 | 0.020 |
Why?
|
| Anesthetics, Inhalation | 1 | 2012 | 570 | 0.020 |
Why?
|
| Physical Stimulation | 1 | 2009 | 525 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2009 | 1420 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2003 | 5709 | 0.020 |
Why?
|
| Neoplasms | 2 | 2017 | 21672 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2009 | 9735 | 0.020 |
Why?
|
| Gadolinium | 1 | 2011 | 952 | 0.020 |
Why?
|
| Biological Transport | 1 | 2010 | 2120 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 13990 | 0.020 |
Why?
|
| Cytokines | 1 | 2020 | 7326 | 0.020 |
Why?
|
| Metabolome | 1 | 2012 | 895 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 2886 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 6313 | 0.020 |
Why?
|
| Speech Perception | 1 | 2009 | 489 | 0.020 |
Why?
|
| Calibration | 1 | 2007 | 816 | 0.020 |
Why?
|
| Speech | 1 | 2009 | 540 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 1016 | 0.010 |
Why?
|
| Aged, 80 and over | 3 | 2009 | 57768 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 4752 | 0.010 |
Why?
|
| Fasting | 1 | 2009 | 1591 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2020 | 11478 | 0.010 |
Why?
|
| Frontal Lobe | 1 | 2009 | 1407 | 0.010 |
Why?
|
| Equipment Design | 1 | 2010 | 3582 | 0.010 |
Why?
|
| Fixation, Ocular | 1 | 2002 | 251 | 0.010 |
Why?
|
| Diffusion | 1 | 2002 | 833 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 10949 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2003 | 1525 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2009 | 5076 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2009 | 2925 | 0.010 |
Why?
|
| Prognosis | 1 | 2019 | 29050 | 0.010 |
Why?
|
| Anisotropy | 1 | 2002 | 1265 | 0.010 |
Why?
|
| Neural Pathways | 1 | 2009 | 2972 | 0.010 |
Why?
|
| Neurosurgical Procedures | 1 | 2009 | 2003 | 0.010 |
Why?
|
| Cadaver | 1 | 2002 | 1337 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2000 | 981 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2020 | 40559 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2021 | 53280 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 11368 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 13668 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2009 | 6196 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 16687 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 8426 | 0.010 |
Why?
|
| Survival Rate | 1 | 2009 | 12781 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 8321 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2003 | 6461 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 1998 | 805 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2020 | 77426 | 0.010 |
Why?
|
| Inflammation | 1 | 2011 | 10634 | 0.010 |
Why?
|
| ROC Curve | 1 | 1998 | 3527 | 0.010 |
Why?
|
| United States | 1 | 2018 | 69867 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2002 | 12035 | 0.010 |
Why?
|
| Adolescent | 2 | 2009 | 85759 | 0.000 |
Why?
|
| Diet | 1 | 2002 | 7937 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2009 | 63119 | 0.000 |
Why?
|
Concepts
(252)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(45)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_